Greg Tourangeau is Principal Accounting Officer of Fulcrum Therapeutics, Inc.. Currently has a direct ownership of 14,062 shares of FULC, which is worth approximately $111,652. The most recent transaction as insider was on May 08, 2025, when has been sold 498 shares (Common Stock) at a price of $5.06 per share, resulting in proceeds of $2,519. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 14.1K
21.53% 3M change
21.53% 12M change
Total Value Held $111,652

Greg Tourangeau Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 08 2025
SELL
Open market or private sale
$2,519 $5.06 p/Share
498 Reduced 3.42%
14,062 Common Stock
May 07 2024
SELL
Open market or private sale
$1,831 $7.76 p/Share
236 Reduced 2.0%
11,571 Common Stock
Mar 08 2024
SELL
Open market or private sale
$57,240 $11.72 p/Share
4,884 Reduced 29.26%
11,807 Common Stock
May 10 2023
SELL
Open market or private sale
$695 $3.31 p/Share
210 Reduced 1.3%
15,992 Common Stock
May 06 2022
BUY
Grant, award, or other acquisition
-
3,250 Added 16.71%
16,202 Common Stock
GT

Greg Tourangeau

Principal Accounting Officer
Cambridge, MA

Track Institutional and Insider Activities on FULC

Follow Fulcrum Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FULC shares.

Notify only if

Insider Trading

Get notified when an Fulcrum Therapeutics, Inc. insider buys or sells FULC shares.

Notify only if

News

Receive news related to Fulcrum Therapeutics, Inc.

Track Activities on FULC